Pacira BioSciences Inc (NASDAQ: PCRX) on Tuesday, plunged -2.31% from the previous trading day, before settling in for the closing price of $29.05. Within the past 52 weeks, PCRX’s price has moved between $25.33 and $40.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 15.46% over the last five years. The company achieved an average annual earnings per share of -1.29%. With a float of $45.14 million, this company’s outstanding shares have now reached $46.48 million.
The firm has a total of 712 workers. Let’s measure their productivity.
Pacira BioSciences Inc (PCRX) Insider Activity
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Pacira BioSciences Inc is 3.03%, while institutional ownership is 107.90%. The most recent insider transaction that took place on Jun 13 ’24, was worth 211,488. In this transaction Chief Administrative Officer of this company sold 7,452 shares at a rate of $28.38, taking the stock ownership to the 102,912 shares. Before that another transaction happened on Jun 13 ’24, when Company’s Chief Operating Officer sold 1,000 for $28.38, making the entire transaction worth $28,380. This insider now owns 116,040 shares in total.
Pacira BioSciences Inc (PCRX) Earnings and Forecasts
As on 3/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0.78 earnings per share (EPS) for the period topping the consensus outlook (set at 0.76) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.29% per share during the next fiscal year.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
Pacira BioSciences Inc (PCRX) is currently performing well based on its current performance indicators. A quick ratio of 4.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.94. Likewise, its price to free cash flow for the trailing twelve months is 7.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.39, a number that is poised to hit 0.68 in the next quarter and is forecasted to reach 3.58 in one year’s time.
Technical Analysis of Pacira BioSciences Inc (PCRX)
Analysing the last 5-days average volume posted by the [Pacira BioSciences Inc, PCRX], we can find that recorded value of 1.08 million was better than the volume posted last year of 0.62 million. As of the previous 9 days, the stock’s Stochastic %D was 54.96%. Additionally, its Average True Range was 1.08.
During the past 100 days, Pacira BioSciences Inc’s (PCRX) raw stochastic average was set at 41.67%, which indicates a significant increase from 30.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.25% in the past 14 days, which was lower than the 38.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.53, while its 200-day Moving Average is $29.78. Now, the first resistance to watch is $28.86. This is followed by the second major resistance level at $29.35. The third major resistance level sits at $29.60. If the price goes on to break the first support level at $28.12, it is likely to go to the next support level at $27.87. Should the price break the second support level, the third support level stands at $27.38.
Pacira BioSciences Inc (NASDAQ: PCRX) Key Stats
Market capitalization of the company is 1.32 billion based on 46,546K outstanding shares. Right now, sales total 674,980 K and income totals 41,960 K. The company made 167,120 K in profit during its latest quarter, and 8,980 K in sales during its previous quarter.
